Literature DB >> 22781844

Transient inactivation of the neonatal ventral hippocampus impairs attentional set-shifting behavior: reversal with an α7 nicotinic agonist.

Julie M Brooks1, Michelle L Pershing, Morten S Thomsen, Jens D Mikkelsen, Martin Sarter, John P Bruno.   

Abstract

Cognitive deficits represent a core symptom cluster in schizophrenia that are thought to reflect developmental dysregulations within a neural system involving the ventral hippocampus (VH), nucleus accumbens (NAC), and prefrontal cortex (PFC). The present experiments determined the cognitive effects of transiently inactivating VH in rats during a sensitive period of development. Neonatal (postnatal day 7, PD7) and adolescent (PD32) male rats received a single bilateral infusion of saline or tetrodotoxin (TTX) within the VH to transiently inactivate local circuitry and efferent outflow. Rats were tested as adults on an attentional set-shifting task. Performance in this task depends upon the integrity of the PFC and NAC. TTX infusions did not affect the initial acquisition or ability to learn an intra-dimensional shift. However, TTX rats required a greater number of trials than did controls to acquire the first reversal and extra-dimensional shift (ED) stages. These impairments were age and region-specific as rats infused with TTX into the VH at PD32, or into the dorsal hippocampus at PD7, exhibited performance in the task similar to that of controls. Finally, acute systemic administration of the partial α7 nicotinic acetylcholine receptor (nAChR) agonist SSR 180711 (3.0 mg/kg) eliminated the TTX-induced performance deficits. Given that patients with schizophrenia exhibit hippocampal pathophysiology and deficits in the ED stages of set-shifting tasks, our results support the significance of transient hippocampal inactivation as an animal model for studying the cognitive impairments in schizophrenia as well as the pro-cognitive therapeutic potential of α7 nAChR agonists.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22781844      PMCID: PMC3442342          DOI: 10.1038/npp.2012.106

Source DB:  PubMed          Journal:  Neuropsychopharmacology        ISSN: 0893-133X            Impact factor:   7.853


  84 in total

1.  Projections from the nucleus accumbens to cholinergic neurons of the ventral pallidum: a correlated light and electron microscopic double-immunolabeling study in rat.

Authors:  L Záborszky; W E Cullinan
Journal:  Brain Res       Date:  1992-01-20       Impact factor: 3.252

2.  Synaptic interactions among excitatory afferents to nucleus accumbens neurons: hippocampal gating of prefrontal cortical input.

Authors:  P O'Donnell; A A Grace
Journal:  J Neurosci       Date:  1995-05       Impact factor: 6.167

3.  NMDA and dopamine interactions in the nucleus accumbens modulate cortical acetylcholine release.

Authors:  Amy Zmarowski; Martin Sarter; John P Bruno
Journal:  Eur J Neurosci       Date:  2005-10       Impact factor: 3.386

Review 4.  A thalamo-hippocampal-ventral tegmental area loop may produce the positive feedback that underlies the psychotic break in schizophrenia.

Authors:  John E Lisman; Hyun Jae Pi; Yuchun Zhang; Nonna A Otmakhova
Journal:  Biol Psychiatry       Date:  2010-05-31       Impact factor: 13.382

Review 5.  Unraveling the attentional functions of cortical cholinergic inputs: interactions between signal-driven and cognitive modulation of signal detection.

Authors:  Martin Sarter; Michael E Hasselmo; John P Bruno; Ben Givens
Journal:  Brain Res Brain Res Rev       Date:  2005-02

Review 6.  Learning and cognitive flexibility: frontostriatal function and monoaminergic modulation.

Authors:  Angie A Kehagia; Graham K Murray; Trevor W Robbins
Journal:  Curr Opin Neurobiol       Date:  2010-02-16       Impact factor: 6.627

7.  alpha(7) Nicotinic acetylcholine receptor activation prevents behavioral and molecular changes induced by repeated phencyclidine treatment.

Authors:  Morten S Thomsen; Ditte Z Christensen; Henrik H Hansen; John P Redrobe; Jens D Mikkelsen
Journal:  Neuropharmacology       Date:  2009-02-21       Impact factor: 5.250

8.  Asenapine restores cognitive flexibility in rats with medial prefrontal cortex lesions.

Authors:  David S Tait; Hugh M Marston; Mohammed Shahid; Verity J Brown
Journal:  Psychopharmacology (Berl)       Date:  2008-10-17       Impact factor: 4.530

9.  Alpha-7 nicotinic acetylcholine receptor agonists selectively activate limbic regions of the rat forebrain: an effect similar to antipsychotics.

Authors:  Henrik H Hansen; Daniel B Timmermann; Dan Peters; Carrie Walters; M Imad Damaj; Jens D Mikkelsen
Journal:  J Neurosci Res       Date:  2007-06       Impact factor: 4.164

Review 10.  The neonatal ventral hippocampal lesion as a heuristic neurodevelopmental model of schizophrenia.

Authors:  Kuei Y Tseng; R Andrew Chambers; Barbara K Lipska
Journal:  Behav Brain Res       Date:  2008-12-03       Impact factor: 3.332

View more
  19 in total

1.  Pro-cognitive activity in rats of 3-furan-2-yl-N-p-tolyl-acrylamide, a positive allosteric modulator of the α7 nicotinic acetylcholine receptor.

Authors:  A Potasiewicz; T Kos; F Ravazzini; G Puia; H R Arias; P Popik; A Nikiforuk
Journal:  Br J Pharmacol       Date:  2015-10-10       Impact factor: 8.739

Review 2.  Translation-Focused Approaches to GPCR Drug Discovery for Cognitive Impairments Associated with Schizophrenia.

Authors:  Cassandra J Hatzipantelis; Monica Langiu; Teresa H Vandekolk; Tracie L Pierce; Jess Nithianantharajah; Gregory D Stewart; Christopher J Langmead
Journal:  ACS Pharmacol Transl Sci       Date:  2020-10-28

3.  Old dog, new tricks: the attentional set-shifting test as a novel cognitive behavioral task after controlled cortical impact injury.

Authors:  Corina O Bondi; Jeffrey P Cheng; Heather M Tennant; Christina M Monaco; Anthony E Kline
Journal:  J Neurotrauma       Date:  2014-04-10       Impact factor: 5.269

4.  Corresponding decrease in neuronal markers signals progressive parvalbumin neuron loss in MAM schizophrenia model.

Authors:  Kathryn M Gill; Anthony A Grace
Journal:  Int J Neuropsychopharmacol       Date:  2014-04-30       Impact factor: 5.176

5.  The alpha-7 nicotinic receptor partial agonist/5-HT3 antagonist RG3487 enhances cortical and hippocampal dopamine and acetylcholine release.

Authors:  Mei Huang; Anna R Felix; Sunoh Kwon; David Lowe; Tanya Wallace; Luca Santarelli; Herbert Y Meltzer
Journal:  Psychopharmacology (Berl)       Date:  2013-12-07       Impact factor: 4.530

6.  Elevated levels of kynurenic acid during gestation produce neurochemical, morphological, and cognitive deficits in adulthood: implications for schizophrenia.

Authors:  Michelle L Pershing; David M Bortz; Ana Pocivavsek; Peter J Fredericks; Christinna V Jørgensen; Sarah A Vunck; Benedetta Leuner; Robert Schwarcz; John P Bruno
Journal:  Neuropharmacology       Date:  2014-11-01       Impact factor: 5.250

Review 7.  Found in translation: Understanding the biology and behavior of experimental traumatic brain injury.

Authors:  Corina O Bondi; Bridgette D Semple; Linda J Noble-Haeusslein; Nicole D Osier; Shaun W Carlson; C Edward Dixon; Christopher C Giza; Anthony E Kline
Journal:  Neurosci Biobehav Rev       Date:  2014-12-10       Impact factor: 8.989

Review 8.  nAChR dysfunction as a common substrate for schizophrenia and comorbid nicotine addiction: Current trends and perspectives.

Authors:  Vinay Parikh; Munir Gunes Kutlu; Thomas J Gould
Journal:  Schizophr Res       Date:  2016-01-21       Impact factor: 4.939

9.  The impact of cafeteria diet feeding on physiology and anxiety-related behaviour in male and female Sprague-Dawley rats of different ages.

Authors:  Wiebke Warneke; Susanne Klaus; Heidrun Fink; Simon C Langley-Evans; Jörg-Peter Voigt
Journal:  Pharmacol Biochem Behav       Date:  2013-11-21       Impact factor: 3.533

10.  Cognitive rigidity and BDNF-mediated frontostriatal glutamate neuroadaptations during spontaneous nicotine withdrawal.

Authors:  Robert D Cole; Matty Zimmerman; Anastasia Matchanova; Munir Gunes Kutlu; Thomas J Gould; Vinay Parikh
Journal:  Neuropsychopharmacology       Date:  2019-11-21       Impact factor: 7.853

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.